C Xin1,2, J Liu1, J Zhang1, D Zhu1, H Wang1, L Xiong3, Y Lee1, J Ye4, K Lian1, C Xu1, L Zhang1, Q Wang1, Y Liu1, L Tao1. 1. Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. 2. Department of Cardiology, The Second Artillery General Hospital of Chinese Peoples's Liberation Army, Beijing, China. 3. Department of Anesthesiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. 4. Department of Pathology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Abstract
BACKGROUND/ OBJECTIVES: It has been reported that irisin regulated exercise-mediated adipocyte browning; however, the systematical effects of irisin on the metabolism of glucose and lipid in diabetes are largely unknown. In the present study, we investigated the role and underlying mechanism of irisin in glucose utilization and lipid metabolism in diabetic mice. METHODS: A mouse model of diabetes was established by feeding C57BL/6 mice with high-fat diet. The diabetic mice were then treated with irisin. To mimic type 2 diabetes in vitro, myocytes and hepatocytes were cultured in a medium of high glucose and high fat. Glucose uptake, fatty acid oxidation and the expression of related protein were evaluated. RESULTS: Irisin improved glucose tolerance and glucose uptake as evidenced by increased (18)F-FDG accumulation and GLUT4 translocation in diabetic skeletal muscle. Irisin also increased glucose uptake in myocytes cultured in high glucose/high fatty acid medium. In contrast, irisin reduced the expression of PEPCK and G6Pase, which are involved in gluconeogenesis, in diabetic liver. Consistently, irisin reduced fat weight and serum total cholesterol and triglyceride levels in diabetic mice, but increased acetyl coenzyme A carboxylase-β phosphorylation in muscle tissue and uncoupling protein 1 expression in fat tissue. In addition, irisin increased the oxidation of fatty acid in myocytes. Knockdown of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) attenuated the effects of irisin on glucose uptake and fatty acid β-oxidation in myocytes. Similarly, inhibition of AMPK by a specific inhibitor reduced the effects of irisin on PEPCK and G6Pase expression in hepatocytes. CONCLUSIONS: Our results suggest that irisin has an essential role in glucose utilization and lipid metabolism, and irisin is a promising pharmacological target for the treatment of diabetes and its complications.
BACKGROUND/ OBJECTIVES: It has been reported that irisin regulated exercise-mediated adipocyte browning; however, the systematical effects of irisin on the metabolism of glucose and lipid in diabetes are largely unknown. In the present study, we investigated the role and underlying mechanism of irisin in glucose utilization and lipid metabolism in diabeticmice. METHODS: A mouse model of diabetes was established by feeding C57BL/6 mice with high-fat diet. The diabeticmice were then treated with irisin. To mimic type 2 diabetes in vitro, myocytes and hepatocytes were cultured in a medium of high glucose and high fat. Glucose uptake, fatty acid oxidation and the expression of related protein were evaluated. RESULTS: Irisin improved glucose tolerance and glucose uptake as evidenced by increased (18)F-FDG accumulation and GLUT4 translocation in diabetic skeletal muscle. Irisin also increased glucose uptake in myocytes cultured in high glucose/high fatty acid medium. In contrast, irisin reduced the expression of PEPCK and G6Pase, which are involved in gluconeogenesis, in diabetic liver. Consistently, irisin reduced fat weight and serum total cholesterol and triglyceride levels in diabeticmice, but increased acetyl coenzyme A carboxylase-β phosphorylation in muscle tissue and uncoupling protein 1 expression in fat tissue. In addition, irisin increased the oxidation of fatty acid in myocytes. Knockdown of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) attenuated the effects of irisin on glucose uptake and fatty acid β-oxidation in myocytes. Similarly, inhibition of AMPK by a specific inhibitor reduced the effects of irisin on PEPCK and G6Pase expression in hepatocytes. CONCLUSIONS: Our results suggest that irisin has an essential role in glucose utilization and lipid metabolism, and irisin is a promising pharmacological target for the treatment of diabetes and its complications.
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: A Gastaldelli; S Baldi; M Pettiti; E Toschi; S Camastra; A Natali; B R Landau; E Ferrannini Journal: Diabetes Date: 2000-08 Impact factor: 9.461
Authors: W Farrash; M Brook; H Crossland; B E Phillips; J Cegielski; D J Wilkinson; D Constantin-Teodosiu; P L Greenhaff; K Smith; M Cleasby; P J Atherton Journal: Am J Physiol Endocrinol Metab Date: 2020-05-05 Impact factor: 4.310
Authors: Naohiro Yano; Ling Zhang; Dennis Wei; Patrycja M Dubielecka; Lei Wei; Shougang Zhuang; Ping Zhu; Gangjian Qin; Paul Y Liu; Y Eugene Chin; Ting C Zhao Journal: Am J Physiol Endocrinol Metab Date: 2020-03-17 Impact factor: 4.310